Abstract
Summary The global pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2, also referred to as COVID-19) rapidly became an unprecedented healthcare challenge. It represents a particular concern for patients with inflammatory bowel disease (IBD), many of whom require treatment with immunosuppressive medication which may be associated with an increased risk of both viral and bacterial infections (Gastroenterology 2018;155(2):337-346.e10). Moreover, as IBD is a lifelong condition, patients are frequently older with comorbidities, further increasing the potential risks of a more severe COVID-19 disease course. This has led to considerable uncertainty over appropriate treatment of IBD in the COVID-19 era, and has brought safety considerations into the focus of the patients and physicians.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
